Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to $8.2 million.

  • Syndax Pharmaceuticals' Net Cash Flow fell 70.42% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.2 million, marking a year-over-year decrease of 142.14%. This contributed to the annual value of -$141.3 million for FY2024, which is 163.90% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Net Cash Flow stood at $8.2 million for Q3 2025, which was up 118.02% from -$45.4 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Net Cash Flow's 5-year high stood at $200.8 million during Q4 2023, with a 5-year trough of -$180.8 million in Q1 2024.
  • Its 3-year average for Net Cash Flow is $3.9 million, with a median of -$90,000 in 2025.
  • Its Net Cash Flow has fluctuated over the past 5 years, first slumped by 1,975.08% in 2022, then skyrocketed by 6,641.99% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Net Cash Flow (Quarterly) stood at $150.5 million in 2021, then plummeted by 98.02% to $3.0 million in 2022, then soared by 6,641.99% to $200.8 million in 2023, then slumped by 89.51% to $21.1 million in 2024, then crashed by 70.42% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, -$45.4 million for Q2 2025, and -$90,000 during Q1 2025.